Pseudomonas aeruginosa Bacteriophage PA1Ø Requires Type IV Pili for Infection and Shows Broad Bactericidal and Biofilm Removal Activities

ABSTRACT We isolated a new lytic Pseudomonas aeruginosa phage that requires type IV pili for infection. PA1Ø has a broad bactericidal spectrum, covering Gram-positive and Gram-negative bacteria, and can eradicate biofilm cells. PA1Ø may be developed as a therapeutic agent for biofilm-related mixed infections with P. aeruginosa and Staphylococcus aureus.

[1]  Anren Hu,et al.  Antibacterial activity of Acinetobacter baumannii phage ϕAB2 endolysin (LysAB2) against both Gram-positive and Gram-negative bacteria , 2011, Applied Microbiology and Biotechnology.

[2]  C. Lan,et al.  Production and application of bacteriophage and bacteriophage-encoded lysins. , 2009, Recent patents on biotechnology.

[3]  A. Nicolau,et al.  Efficacy of a Broad Host Range Lytic Bacteriophage Against E. coli Adhered to Urothelium , 2011, Current Microbiology.

[4]  H. Ackermann.  Phage classification and characterization. , 2009, Methods in molecular biology.

[5]  Jungmin Kim,et al.  Complete Genome Sequence of Pseudomonas aeruginosa Lytic Bacteriophage PA1Ø Which Resembles Temperate Bacteriophage D3112 , 2012, Journal of Virology.

[6]  S. Lory,et al.  A signaling network reciprocally regulates genes associated with acute infection and chronic persistence in Pseudomonas aeruginosa. , 2004, Developmental cell.

[7]  D. Guttman,et al.  Complete Sequence and Evolutionary Genomic Analysis of the Pseudomonas aeruginosa Transposable Bacteriophage D3112 , 2004, Journal of bacteriology.

[8]  M. Vaneechoutte,et al.  European regulatory conundrum of phage therapy. , 2007, Future microbiology.

[9]  Jungmin Kim,et al.  A simple colorimetric method for testing antimicrobial susceptibility of biofilmed bacteria , 2010, The Journal of Microbiology.

[10]  R. Zuerner,et al.  Purification and characterization of VSH-1, a generalized transducing bacteriophage of Serpulina hyodysenteriae , 1997, Journal of bacteriology.

[11]  A. Darzins,et al.  Pseudomonas aeruginosa transposable bacteriophages D3112 and B3 require pili and surface growth for adsorption , 1990, Journal of bacteriology.

[12]  M. Mathur,et al.  Bacteriophage therapy: an alternative to conventional antibiotics. , 2003, The Journal of the Association of Physicians of India.

[13]  P. Knežević,et al.  A colorimetric microtiter plate method for assessment of phage effect on Pseudomonas aeruginosa biofilm. , 2008, Journal of microbiological methods.

[14]  C. Jessup,et al.  Ecology and evolution in microbial systems: the generation and maintenance of diversity in phage-host interactions. , 2008, Research in microbiology.

[15]  G. Volckaert,et al.  Quality-Controlled Small-Scale Production of a Well-Defined Bacteriophage Cocktail for Use in Human Clinical Trials , 2009, PloS one.

[16]  Toshikazu Tani,et al.  Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases , 2005, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[17]  K. Salmon,et al.  Characterization of the lysogenic repressor (c) gene of the Pseudomonas aeruginosa transposable bacteriophage D3112. , 2000, Virology.

[18]  A. Darzins,et al.  Mini-D3112 bacteriophage transposable elements for genetic analysis of Pseudomonas aeruginosa , 1989, Journal of bacteriology.